Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the EU, announced today that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma.

8 Aug 2014

Scientists make seminal breakthrough in understanding molecular basis of fibroadenoma

A multi-disciplinary team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, and Singapore General Hospital have made a seminal breakthrough in understanding the molecular basis of fibroadenoma, one of the most common breast tumours diagnosed in women.

21 Jul 2014

First patient successfully treated for symptomatic uterine fibroids with Gynesonics' VizAblate System

Gynesonics, Inc., a women's healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the first treatment of a patient in Cologne, Germany, using the Company's newly-designed VizAblate System.

24 Jun 2014

InSightec inaugurates first centers in Shanghai

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that the first centers in China offering ExAblate, for non-invasive treatment of uterine fibroids, have opened in Shanghai.

30 May 2014

MRI-guided focused ultrasound to treat pain from bone metastases

InSightec Ltd, the leader in magnetic resonance imaging guided Focused Ultrasound therapy (MRgFUS), announced that the results of its ExAblate® Phase III clinical trial for treating painful bone metastases have been published online in the JNCI, Journal of National Cancer Institute.

8 May 2014

New phase III clinical trial shows non-invasive focused ultrasound treatment relieves cancer pain

When cancer progresses and spreads to the bone, patients often suffer debilitating pain. Now, a new phase III clinical trial shows that non-invasive magnetic resonance guided focused ultrasound treatment that heats the cancer within the bone, relieves pain and improves function for most patients when other treatment options are limited.

6 May 2014

Majority of women experience increased amount and duration of bleeding episodes, say researchers

Women going through menopause most likely think of it as the time for an end to predictable monthly periods. Researchers at the University of Michigan say it's normal, however, for the majority of them to experience an increase in the amount and duration of bleeding episodes, which may occur at various times throughout the menopausal transition.

16 Apr 2014

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China.

10 Apr 2014

Researchers use ultrasound to destroy cancerous tissue in brain

Researchers in Zurich, Switzerland have successfully used focused ultrasound for the first time to non-invasively ablate part of a recurrent glioma tumor through a patient's intact skull.

7 Apr 2014

Report highlights benefits of different access approach to treat uterine fibroids

Interventional radiologists have devised a new way to access a woman's fibroids-by flipping her wrist and treating via an arm not groin artery-to nonsurgically shrink noncancerous growths in the muscular wall of the uterus. Researchers found this to be less painful and traumatic for women, allowing them to immediately sit up and move after uterine fibroid embolization (UFE)-with no overnight stay, according to a March article in the Society of Interventional Radiology's flagship publication, the Journal of Vascular and Interventional Radiology.

6 Mar 2014

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.

10 Feb 2014

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum for the treatment of frozen shoulder syndrome (adhesive capsulitis).

16 Dec 2013

Boston Scientific's Direxion Torqueable Microcatheter receives FDA clearance and CE Mark approval

Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation has received U.S. Food and Drug Administration clearance and CE Mark approval for its Direxion Torqueable Microcatheter.

20 Nov 2013

Findings shed light on the impact, treatment concerns related to uterine fibroids

Uterine fibroids cause significant fear and morbidity and can compromise workplace performance, according to a recently published survey of nearly 1,000 women in the U.S. The results were published this month in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health.

24 Oct 2013

Uterine fibroids disproportionately impact African American women

A national survey has found that uterine fibroids have a disproportionate impact on African American women, causing more severe symptoms, interfering with their daily life, and causing them to miss work. These new findings are reported in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

10 Oct 2013

Researchers discover new procedure for treatment of uterine fibroids

Jersey Shore University Medical Center announces today that Mark Martens, M.D., chief of Obstetrics and Gynecology, performed the first Acessa procedure in New Jersey. The procedure is used for the treatment of uterine fibroids. Additionally, Jersey Shore's Jocelyn A. Carlo, M.D., Obstetrics/Gynecology, is performing the procedure.

1 Oct 2013

InSightec: First patient treated in ExAblate Neuro Phase III pivotal trial for tremor

InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients.

11 Sep 2013

New research initiative to focus on ultrasound therapy

The Focused Ultrasound Foundation and Philips have entered into an innovative public-private collaboration with The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust.

6 Sep 2013

Acessa Procedure: The Fibroid Treatment Collaborative's primary surgical therapy for uterine fibroids

The Fibroid Treatment Collaborative, with centers in Chicago, IL and Austin TX, announced today the adoption of the Acessa Procedure as its primary surgical therapy for patients suffering from uterine fibroids.

25 Jul 2013

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

Scientists make seminal breakthrough in understanding molecular basis of fibroadenoma

First patient successfully treated for symptomatic uterine fibroids with Gynesonics' VizAblate System

InSightec inaugurates first centers in Shanghai

MRI-guided focused ultrasound to treat pain from bone metastases

New phase III clinical trial shows non-invasive focused ultrasound treatment relieves cancer pain

Majority of women experience increased amount and duration of bleeding episodes, say researchers

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

Researchers use ultrasound to destroy cancerous tissue in brain

Report highlights benefits of different access approach to treat uterine fibroids

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

Boston Scientific's Direxion Torqueable Microcatheter receives FDA clearance and CE Mark approval

Findings shed light on the impact, treatment concerns related to uterine fibroids

Uterine fibroids disproportionately impact African American women

Researchers discover new procedure for treatment of uterine fibroids

InSightec: First patient treated in ExAblate Neuro Phase III pivotal trial for tremor

New research initiative to focus on ultrasound therapy

Acessa Procedure: The Fibroid Treatment Collaborative's primary surgical therapy for uterine fibroids

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in